# Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

> **NCT06541327** · — · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Chimeric Antigen Receptor

## Key facts

- **NCT ID:** NCT06541327
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2040-12-31
- **Final completion:** 2040-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541327, "Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06541327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*